You are about to leave a GSK website

Third party content disclaimers

 

You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independently operated and not managed by GSK. The website you are linking to is not controlled or endorsed by GSK and GSK assumes no responsibility for the content on the website. If you wish to proceed, click "OK". If you do not wish to leave this website, click “CANCEL”.

OK

CANCEL

Product menu

It's time to Start Strong


It's time to Start Strong

Did you know that patients with COPD have often lost 50% of their lung function when they begin to experience symptoms?1–3

It’s time to optimise COPD treatment early for your symptomatic patients with a LAMA/LABA, as recommended by GOLD guidelines.*3

Offer your newly-diagnosed, symptomatic patients maximal bronchodilation right from the start.3,4

“At first, he thought he was just getting old. But then many activities became a struggle, even leaving the house.”

– A story on Edward, a 62-year-old electrician and amateur ballroom dancer, newly diagnosed with COPD.

See how early optimisation with a LAMA/LABA improved Edward's symptoms and quality of life.

Hypothetical patient with a typical CAT score of 10–20. For illustrative purposes only and may not be representative of all COPD patients.

Why should you choose to Start Strong with ANORO Ellipta?

Only ANORO Ellipta offers superior lung function improvement vs other initial maintenance options, including other LAMA/LABAs.†5–13

ANORO improves patients’ lung function and reduces reliance on rescue medication:

Lungs

The only LAMA/LABA to show superior lung function improvement within the class5–7,10

2x Icon

greater chance of clinically meaningful (≥100 mL) improvements in lung function vs TIO/OLO‡5

Inhaler

38% extra reduction in rescue medication use vs TIO/OLO‡5

See how ANORO compares with other LAMA/LABAs:

  MOLECULES   

    DEVICE   

DOWNLOAD THE FACTSHEET

The latest generation molecules in ANORO

Only ANORO contains umeclidinium and vilanterol, two molecules that target receptors with high affinity and selectivity, for a 24-hour benefit.¶14–20

See how umeclidinium and vilanterol provide sustained bronchodilation through separate but complementary modes of action.7,14–19,21

See the benefits of the Ellipta device, and how it compares to other commonly used COPD inhalers.

Delivered to your patients through the easy-to-use Ellipta device.22–24

Give your symptomatic patients with COPD the maximal bronchodilation they need, and choose to Start Strong with ANORO.5,8,11

    View ANORO's Efficacy   

*Guideline recommendations refer to drug classes, not specific products.3 

†GOLD recognise LAMA/LABA as the cornerstone of initial maintenance for the majority of symptomatic patients suffering from dyspnoea. “Other initial maintenance options” refers to monotherapy and LAMA/LABA only (initial maintenance with triple therapy, as per GOLD Group E, is excluded). ICS/LABA is no longer recommended by GOLD. GOLD recommendations refer to drug classes, not specific products.3 ANORO is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.21

‡Responder analysis. Odds based on response vs non-response change from baseline of ANORO (n=234; 66%), Tiotropium/olodaterol (TIO/OLO 5/5 mcg; n=229; 48%); OR: 2.05; 95% CI: 1.34, 3.14; p<0.001.5 MCID: ≥100 mL improvement in trough FEV1.25

§Rescue albuterol/salbutamol therapy reduced by 0.94 puffs/day for ANORO (n=222) vs 0.68 puffs/day for Tiotropium/olodaterol (TIO/OLO 5/5 mcg; n=217); difference -0.25 (95% CI:-0.37, -0.14; p<0.001).5

The clinical relevance of in vitro data or data derived from animal studies is unknown. Vilanterol monotherapy is not licensed for COPD.

ANORO Ellipta (umeclidinium and vilanterol) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.21

ANORO Ellipta Safety Information21

Special warnings and precautions for use:

  • Umeclidinium/vilanterol should not be used in patients with asthma since it has not been studied in this patient population.
  • Umeclidinium/vilanterol is not indicated for the treatment of acute episodes of bronchospasm.
  • Increasing use of short-acting bronchodilators to relieve symptoms indicates deterioration of control. In the event of deterioration of COPD during treatment with umeclidinium/vilanterol, a re-evaluation of the patient and of the COPD treatment regimen should be undertaken.
  • Umeclidinium/vilanterol should be used with caution in patients with convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to bea2-andrenergic agonists.

Pregnancy

  • There are no data from the use of umeclidinium/vilanterol in pregnant women. Studies in animals have shown reproductive toxicity at exposures which are not clinically relevant after administration of vilanterol.

Adverse Events: Common adverse events (≥1/100 to <1/10) include urinary tract infection, sinusitis, nasopharyngitis, pharyngitis, upper respiratory tract infection, cough, oropharyngeal pain, constipation, and dry mouth.

Abbreviations 

CI, confidence interval; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV1, forced expiratory volume in one second; ICS, inhaled corticosteroid; LABA, long-acting beta-2 agonist; LAMA, long-acting muscarinic antagonist; MCID minimal clinically important difference; OLO, olodaterol; OR, odds ratio; TIO, tiotropium.

References

  1. Sutherland ER, Cherniack RM. N Engl J Med. 2004;350(26):2689–2697.
  2. Mapel DW et al. Int J Chron Obstruct Pulmon Dis. 2011;6:573–581.
  3. GOLD 2024 Report. Global Initiative for Chronic Obstructive Lung Disease. Available at: www.goldcopd.org. Accessed February 2024.
  4. Anzueto A, Miravitlles M. Am J Med 2018;131(6):608–622.
  5. Feldman GJ et al. Adv Ther 2017;34(11):2518–2533.
  6. Alcázar Navarrete B et al. Pulm Ther 2018;4(2):171–183.
  7. Maltais F et al. Adv Ther 2019;36(9):2434–2449.
  8. Maleki-Yazdi MR et al. Adv Ther 2016;33(12):2188–2199.
  9. Data on file; RF/UCV/0112/15;1. REF-0566.
  10. Ismaila AS et al. Adv Ther 2022;39(11):4961–5010.
  11. Maltais F et al. Respir Res 2019;20(1):238.
  12. Singh D et al. BMC Pulm Med 2015;15:91.
  13. Lipson DA et al. N Engl J Med 2018;378(18):1671–1680.
  14. Feldman G et al. Int J Chron Obstruct Pulmon Dis 2016;11(1):719–730.
  15. Slack RJ et al. J Pharmacol Exp Ther 2013;344(1):218–230.
  16. Hanania NA et al. Chest 2012;142(1):119–127.
  17. Kempsford R et al. Pulm Pharmacol Ther 2013;26(2):256–264.
  18. Lainé DI et al. J Med Chem 2009;52(8):2493–2505.
  19. Salmon M et al. J Pharmacol Exp Ther 2013;345(2):260–270.
  20. Babu KS and Morjaria JB. Ther Adv Chronic Dis 2017;8(4–5):81–91.
  21. ANORO Ellipta prescribing information.
  22. van der Palen J et al. NPJ Prim Care Respir Med 2016;26:16079.
  23. Svedsater H et al. BMC Pulm Med 2013;13:72.
  24. Riley JH et al. Int J Chron Obstruct Pulm Dis 2016;11(1):1873–1880.
  25. Jones PW et al. Am J Respir Crit Care Med 2014;189(3):250–255.

Trade marks are owned by or licensed to the GSK group of companies. ANORO Ellipta was developed in collaboration with INNOVIVA 

PM-MY-UCV-WCNT-240001 01/25